Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831383 · ClinicalTrials.gov registry record · NA
The STOP-HPV Scale Up Study
A NA study of Human Papilloma Virus Vaccine, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
- 1
- Study location
NCT06831383: Recruiting NA study of Human Papilloma Virus Vaccine, sponsored by University of California, Los Angeles.
NCT06831383 is a NA study of Human Papilloma Virus Vaccine that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 100,000 participants, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (7033% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06831383, a NA study of Human Papilloma Virus Vaccine, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC). cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.
Primary Outcome
The percent of children ages 9-\<13 years of age who received their first dose of HPV vaccine at or following a well child care visit with a participating provider during the intervention-period (denominator is children ages 9-\<13 with a well child visit during the study period at which they were due for their first dose).
Conditions Studied
Interventions
- BEHAVIORAL STOP-HPV-Online
- BEHAVIORAL STOP-HPV-LC
Study Locations (1)
Virginia
- AMGA - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2027-04-19 |
| Phase | NA |
What NCT06831383 shows while recruiting
NCT06831383 is an interventional study that assigns participants to a tested intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (7033% higher).
The record links to 1 condition, with Human Papilloma Virus Vaccine appearing as the primary indexed condition, and to 2 interventions - of which STOP-HPV-Online is the first listed.
NCT06831383 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06831383 about?
NCT06831383 is a clinical study titled "The STOP-HPV Scale Up Study". Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost eff...
What is the current status of trial NCT06831383?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,000 participants. The study started on 2026-03-23. Estimated completion is 2027-04-19.
What conditions does trial NCT06831383 study?
This clinical trial studies the following conditions: Human Papilloma Virus Vaccine.
What interventions are being tested in trial NCT06831383?
The interventions under investigation include: STOP-HPV-Online (BEHAVIORAL), STOP-HPV-LC (BEHAVIORAL).
Who is sponsoring clinical trial NCT06831383?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831383 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06831383's enrollment target sits among peer trials
100,000 3rd of 2000 higher than 1,998 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI